Analysts Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Earnings of -$0.61 Per Share

Wall Street analysts forecast that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will report earnings per share (EPS) of ($0.61) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Dicerna Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.80) and the highest estimate coming in at ($0.28). Dicerna Pharmaceuticals reported earnings per share of ($0.68) in the same quarter last year, which suggests a positive year over year growth rate of 10.3%. The business is expected to issue its next earnings results on Thursday, March 29th.

Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.22). The company had revenue of $0.47 million for the quarter. Dicerna Pharmaceuticals had a negative return on equity of 293.25% and a negative net margin of 5,895.26%. The business’s quarterly revenue was up 192.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.68) earnings per share.

DRNA has been the topic of a number of recent research reports. Zacks Investment Research cut Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. Chardan Capital reissued a “neutral” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, January 16th. Evercore ISI initiated coverage on Dicerna Pharmaceuticals in a report on Tuesday, January 16th. They set an “outperform” rating and a $14.00 price objective on the stock. ValuEngine raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $10.05.

In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv purchased 285,000 shares of the stock in a transaction on Monday, December 18th. The shares were purchased at an average price of $7.00 per share, with a total value of $1,995,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 29.41% of the company’s stock.

Several large investors have recently added to or reduced their stakes in DRNA. First Manhattan Co. purchased a new stake in shares of Dicerna Pharmaceuticals in the 4th quarter valued at about $3,865,000. Deschutes Portfolio Strategy LLC purchased a new stake in shares of Dicerna Pharmaceuticals in the 3rd quarter valued at about $575,000. Emerald Advisers Inc. PA purchased a new stake in shares of Dicerna Pharmaceuticals in the 4th quarter valued at about $266,000. Birchview Capital LP raised its holdings in shares of Dicerna Pharmaceuticals by 125.0% in the 3rd quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Dicerna Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after acquiring an additional 14,517 shares in the last quarter. 22.76% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Dicerna Pharmaceuticals (NASDAQ DRNA) opened at $9.61 on Wednesday. The stock has a market capitalization of $461.67, a PE ratio of -2.80 and a beta of 2.75. Dicerna Pharmaceuticals has a 1-year low of $2.43 and a 1-year high of $11.19.

COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Earnings of -$0.61 Per Share” was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/07/analysts-anticipate-dicerna-pharmaceuticals-inc-drna-will-post-earnings-of-0-61-per-share.html.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply